Short Interest in Apollomics Inc. (NASDAQ:APLM) Rises By 104.5%

Apollomics Inc. (NASDAQ:APLM) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 5,144 shares, a growth of 104.5% from the June 15th total of 2,515 shares. Based on an average trading volume of 21,851 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are sold short.

Apollomics Trading Down 14.6%

Shares of NASDAQ APLM traded down $3.40 during trading hours on Friday, hitting $19.88. The stock had a trading volume of 5,700 shares, compared to its average volume of 14,185. The firm’s 50-day moving average price is $16.42 and its two-hundred day moving average price is $17.58. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent quarter. Institutional investors own 19.13% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.